

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOAL AND OBJECTIVES	1
REASONS FOR DOING THE STUDY	2
INTENDED AUDIENCE.....	2
SCOPE OF REPORT	3
INFORMATION SOURCES AND METHODOLOGY.....	3
AUTHOR’S CREDENTIALS	4
RELATED REPORTS FROM BCC RESEARCH	4
BCC ONLINE SERVICES.....	5
DISCLAIMER	5
 CHAPTER TWO: SUMMARY.....	 6
SUMMARY.....	6
<i>SUMMARY TABLE GLOBAL ORPHAN DRUGS DEMAND BY VALUE, THROUGH 2014 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL ORPHAN DRUGS DEMAND BY VALUE, 2008-2014 (\$ MILLIONS)</i>	7
 CHAPTER THREE: OVERVIEW	 8
DEFINITION OF AN ORPHAN DRUG	8
HISTORY OF ORPHAN DRUG LEGISLATION	8
FIRST LEGISLATION ON ORPHAN DRUGS.....	8
Amendments to the ODA	8
Bills Passed in 2002 Increased Funding and Established the Office of Rare Diseases	9
Orphan Drug Legislation — Global Status	9
INCENTIVES FOR ORPHAN DRUG DEVELOPMENT	9
THE NEED FOR INCENTIVES	10
<i>TABLE 1 NUMBER OF ORPHAN DRUG DESIGNATIONS AND APPROVALS PER YEAR BY U.S. FDA, 1983-2009</i>	10
APPLICATIONS FOR ORPHAN DRUG DESIGNATIONS HAVE DOUBLED	10
PROFITABILITY OF ORPHAN DRUGS	11
MARKET EXCLUSIVITY.....	11
NO REGULATORY RESTRICTIONS ON PRICING.....	12
OFF-LABEL USE.....	12
CHALLENGES FOR EFFECTIVE USE OF THE ODA	12
MARKET EXCLUSIVITY VERSUS PATENT PROTECTION	13
MARKET SIZE AND KEY PLAYERS	14
<i>TABLE 2 TOP 10 COMPANIES IN THE ORPHAN DRUG MARKET AND THEIR MARKET SHARES (%)</i>	14
THE ORPHAN DRUG ACT — A BONUS FOR BIOTECH	15
BIG PHARMA IS ENTERING THE ORPHAN DRUGS SECTOR AGGRESSIVELY.....	15
CONCERNS ABOUT THE ORPHAN DRUG ACT	16

COST-EFFECTIVENESS.....	16
PRICING OF ORPHAN DRUGS.....	17
TABLE 3 SOME EXAMPLES OF HIGHLY EXPENSIVE ORPHAN DRUGS AND THEIR PRICES.....	17
TABLE 3 (CONTINUED).....	18
HIGH-PRICED ORPHAN DRUGS LEADING TO PRICE CONTROL MEASURES BY GOVERNMENTS	19
TABLE 4 SOME OF THE RECENT CONTROVERSIES RELATED TO ORPHAN DRUGS PRICING.....	20
ACCESS TO ORPHAN DRUGS AND REIMBURSEMENT — CURRENT PRACTICES	21
ORPHAN DRUG ACCESS AND REIMBURSEMENT SCENARIO IN THE U.S.	21
ACCESS AND REIMBURSEMENT SCENARIO IN EUROPE.....	21
TABLE 5 ORPHAN DRUG ACCESS AND REIMBURSEMENT PRACTICES IN EUROPEAN COUNTRIES.....	22
TABLE 5 (CONTINUED).....	23
TABLE 5 (CONTINUED).....	24
CALL FOR UNIFICATION OF ORPHAN DRUG ACCESS ACROSS EUROPE	24
INNOVATIVE APPROACHES OF PRICING AND REIMBURSEMENT	25
TABLE 6 EMERGING TRENDS IN PRICING AND REIMBURSEMENT OF HIGH-PRICED DRUGS.....	25
TABLE 6 (CONTINUED).....	26
HOW EFFECTIVE ODA IS IN PROMOTING RESEARCH ON RARE DISEASES?.....	26
ORPHAN DRUGS-BASED BUSINESS MODELS — CASE STUDIES	27
A NOT-FOR-PROFIT COMPANY	27
A DISEASE FOUNDATION OPERATING AS A VIRTUAL COMPANY	28
TABLE 7 PARTNERSHIP DEALS SIGNED RECENTLY BETWEEN CFFT AND PHARMACEUTICAL INDUSTRY.....	28
TABLE 7 (CONTINUED).....	29
A FOR-PROFIT COMPANY FOCUSED ON RARE DISEASES	29
A SPECIALTY PHARMACY FOCUSING ON ULTRA- ORPHAN DRUGS.....	29
A Specialty Pharmacy ...(Continued)	30
CHAPTER FOUR: WORLDWIDE INDUSTRY STRUCTURE.....	30
GLOBAL AND REGIONAL SALES OF ORPHAN DRUGS	31
TABLE 8 GLOBAL PROJECTED SALES OF ORPHAN DRUGS BY REGION, THROUGH 2014 (\$ MILLIONS)	32
FIGURE 1 GLOBAL PROJECTED SALES OF ORPHAN DRUGS BY REGION, 2008-2014 (\$ MILLIONS).....	32

CATEGORIES OF ORPHAN DRUG MARKET PLAYERS	32
INDUSTRY TRENDS BY SPONSOR TYPES	33
ANALYSIS OF ORPHAN DRUG APPROVALS BY SPONSOR CATEGORIES	33
<i>FIGURE 2 ANALYSIS OF ORPHAN DRUG APPROVALS BY SPONSOR TYPES, 1983-2009 (%)</i>	<i>34</i>
ORPHAN DRUG APPROVALS BY COMPANIES	35
<i>TABLE 9 COMPANIES WITH MORE THAN FIVE ORPHAN DRUG APPROVALS, 1983-2009.....</i>	<i>35</i>
<i>TABLE 9 (CONTINUED).....</i>	<i>36</i>
ORPHAN DRUG REVENUES BY SPONSOR TYPES	36
BIG PHARMA VERSUS BIOTECH COMPANIES	36
<i>TABLE 10 SALES OF LEADING ORPHAN DRUGS — BIG PHARMA VERSUS BIOTECH COMPANIES, 2009 (\$ MILLIONS)</i>	<i>37</i>
<i>TABLE 10 (CONTINUED).....</i>	<i>38</i>
<i>TABLE 10 (CONTINUED).....</i>	<i>39</i>
ORPHAN DRUGS — NOW A STRATEGIC CHOICE FOR THE PHARMA INDUSTRY.....	39
LEADING PLAYERS IN THE GLOBAL ORPHAN DRUG MARKET	40
<i>TABLE 11 TOP 10 COMPANIES IN THE ORPHAN DRUG MARKET AND THEIR REVENUES FROM ORPHAN DRUGS, 2009</i>	<i>41</i>
CHAPTER FIVE: PRODUCTS	42
ORPHAN DRUGS APPROVED BY THE U.S. FDA (1983 – 2009)	42
ORPHAN DRUG DESIGNATIONS AND APPROVALS SINCE 1983.....	42
<i>TABLE 12 NUMBER OF ORPHAN DESIGNATIONS AND APPROVALS BY U.S. FDA, 1983-2009</i>	<i>42</i>
<i>TABLE 12 (CONTINUED).....</i>	<i>43</i>
<i>TABLE 13 ORPHAN DRUG MARKETING APPROVALS BY U.S. FDA PER YEAR, 1983-2009.....</i>	<i>43</i>
<i>TABLE 13 (CONTINUED).....</i>	<i>44</i>
<i>TABLE 13 (CONTINUED).....</i>	<i>45</i>
ORPHAN DRUGS WITH SALES EXCEEDING \$200 MILLION IN 2009	45
<i>TABLE 14 ORPHAN DRUGS WITH GLOBAL SALES EXCEEDING \$200 MILLION, 2009.....</i>	<i>45</i>
<i>TABLE 14 (CONTINUED).....</i>	<i>46</i>
<i>TABLE 14 (CONTINUED).....</i>	<i>47</i>
DETAILED ANALYSIS OF SUCCESSFUL AND PROMISING ORPHAN DRUGS.....	47
ALIMTA	47
Additional indications	48
Future Growth Trends	48
<i>TABLE 15 GLOBAL SALES OF ALIMTA, 2004–2009 (\$ MILLIONS).....</i>	<i>49</i>
AVASTIN	49

Key Indications.....	49
<i>TABLE 16 KEY INDICATIONS FOR AVASTIN GRANTED BY VARIOUS REGULATORY AGENCIES.....</i>	<i>49</i>
<i>TABLE 16 (CONTINUED).....</i>	<i>50</i>
Future Growth Trends	50
AVONEX.....	50
Additional Approvals Gained.....	50
Market Strategies and Future Growth Trends	51
<i>TABLE 17 GLOBAL SALES OF AVONEX, 2000-2009 (\$ MILLIONS).....</i>	<i>52</i>
BETASERON	52
Additional Approvals Gained.....	52
Marketing Strategies and Future Growth Trends.....	53
<i>TABLE 18 GLOBAL SALES OF BETASERON, 2000-2009 (\$ MILLIONS).....</i>	<i>53</i>
BOTOX.....	54
Marketing Strategies and Future Growth Trends.....	54
<i>TABLE 19 GLOBAL SALES OF BOTOX FOR THERAPEUTIC AND COSMETIC USAGES, 2002-2009 (\$ MILLIONS).....</i>	<i>55</i>
COPAXONE.....	55
Marketing Strategies.....	55
<i>TABLE 20 GLOBAL SALES OF COPAXONE, 2002-2009 (\$ MILLIONS).....</i>	<i>56</i>
ENBREL.....	56
Additional Indications	56
Market Strategies.....	57
<i>TABLE 21 U.S. AND INTERNATIONAL SALES OF ENBREL, 2003-2009 (\$ MILLIONS).....</i>	<i>57</i>
EPOGEN.....	58
Recent Threats to Market Share.....	58
<i>TABLE 22 GLOBAL SALES OF EPOGEN, 2000-2009 (\$ MILLIONS).....</i>	<i>59</i>
ERBITUX.....	59
Additional Indications	60
Market Strategies and Future Growth Trends	60
<i>TABLE 23 GLOBAL SALES OF ERBITUX, 2004-2009 (\$ MILLIONS).....</i>	<i>61</i>
EVISTA.....	61
<i>TABLE 24 GLOBAL SALES OF EVISTA, 2003-2009 (\$ MILLIONS).....</i>	<i>62</i>
GLEEVEC.....	62
Approval for Multiple Indications.....	62
Market Strategy and Future Growth Trends.....	63
<i>TABLE 25 GLOBAL SALES OF GLEEVEC, 2001-2009 (\$ MILLIONS).....</i>	<i>63</i>
HUMIRA.....	63
<i>TABLE 26 GLOBAL SALES OF HUMIRA, 2004-2009 (\$ MILLIONS).....</i>	<i>64</i>
INTRON A/PEGINTRON	64
Market Strategy and Future Growth Trends.....	65
<i>TABLE 27 GLOBAL SALES OF INTRON A/PEGINTRON, 2004-2009 (\$ MILLIONS).....</i>	<i>65</i>

KOGENATE	65
<i>TABLE 28 GLOBAL SALES OF KOGENATE, 2001-2009 (\$ MILLIONS)</i>	66
NEUPOGEN/NEULASTA	66
Additional Indications	66
Marketing Strategies.....	67
<i>TABLE 29 GLOBAL SALES OF NEUPOGEN/NEULASTA, 2002-2009 (\$</i> <i>MILLIONS)</i>	67
NOVOSEVEN.....	67
<i>TABLE 30 GLOBAL SALES OF NOVOSEVEN, 2000-2009 (\$</i> <i>MILLIONS)</i>	68
PROGRAF.....	68
Additional Indications	68
Future Prospects.....	69
PROVIGIL	69
REMICADE	70
<i>TABLE 31 GLOBAL SALES OF REMICADE 2001-2009 (\$ MILLIONS)</i>	70
REVLIMID	70
<i>TABLE 32 GLOBAL SALES OF REVLIMID, 2006-2009 (\$ MILLIONS)</i>	71
RITUXAN	71
Additional Indications	71
Characteristics of Market.....	72
<i>TABLE 33 GLOBAL SALES OF RITUXAN, 2000-2009 (\$ MILLIONS)</i>	72
SANDOSTATIN LAR.....	72
TEMODAR.....	73
<i>TABLE 34 GLOBAL SALES OF TEMODAR, 2003-2009 (\$ MILLIONS)</i>	73
TOPAMAX	73
Additional Indications	74
Characteristics of the Market and Future Prospects.....	74
<i>TABLE 35 GLOBAL SALES OF TOPAMAX, 2001-2009 (\$ MILLIONS)</i>	74
TRACLEER	75
<i>TABLE 36 GLOBAL SALES OF TRACLEER, 2002-2009 (\$ MILLIONS)</i>	75
VELCADE.....	75
<i>TABLE 37 GLOBAL SALES OF VELCADE, 2006-2009 (\$ MILLIONS)</i>	76
ZOMETA.....	76
Additional Indications	76
Market Characteristics.....	77
<i>TABLE 38 U.S. AND GLOBAL SALES OF ZOMETA, 2002-2009 (\$</i> <i>MILLIONS)</i>	77
ORPHAN DRUG SALES BY TECHNOLOGY	77
ORPHAN BIOLOGICS	77
Global Sales and Forecasts of Orphan Biologics	78
<i>TABLE 39 SALES AND FORECASTS OF LEADING BIOLOGIC</i> <i>ORPHAN DRUGS, WORLDWIDE, THROUGH 2014 (\$ MILLIONS)</i>	78

<i>FIGURE 3 SALES AND FORECASTS OF LEADING BIOLOGIC ORPHAN DRUGS, WORLDWIDE, 2008-2014 (\$ MILLIONS)</i>	79
SUBCLASSES OF ORPHAN BIOLOGICS.....	79
<i>TABLE 40 SALES AND FORECASTS OF LEADING MONOCLONAL ANTIBODY ORPHAN DRUG SALES, WORLDWIDE, THROUGH 2014 (\$ MILLIONS)</i>	80
<i>FIGURE 4 SALES AND FORECASTS OF LEADING MONOCLONAL ANTIBODY ORPHAN DRUG WORLDWIDE, 2008-2014 (\$ MILLIONS)</i>	80
<i>TABLE 41 GLOBAL SALES AND FORECASTS OF LEADING INTERFERONS WITH ORPHAN DRUG STATUS, THROUGH 2014 (\$ MILLIONS)</i>	81
<i>FIGURE 5 GLOBAL SALES AND FORECASTS OF LEADING INTERFERONS WITH ORPHAN STATUS, 2008-2014 (\$ MILLIONS)</i>	81
<i>TABLE 42 GLOBAL SALES AND FORECASTS OF LEADING GROWTH HORMONES WITH ORPHAN DRUG STATUS, THROUGH 2014 (\$ MILLIONS)</i>	82
<i>FIGURE 6 GLOBAL SALES AND FORECASTS OF LEADING GROWTH HORMONES WITH ORPHAN DRUG STATUS, 2008-2014 (\$ MILLIONS)</i>	83
<i>TABLE 43 GLOBAL SALES AND FORECASTS OF LEADING PLASMA PRODUCT ORPHAN DRUG SALES, THROUGH 2014 (\$ MILLIONS)</i>	83
<i>FIGURE 7 FORECAST OF LEADING PLASMA PRODUCT ORPHAN DRUG SALES, 2008-2014 (\$ MILLIONS)</i>	84
NONBIOLOGIC ORPHAN DRUGS.....	84
<i>TABLE 44 GLOBAL SALES AND FORECASTS OF LEADING NONBIOLOGIC ORPHAN DRUGS, THROUGH 2014 (\$ MILLIONS)</i>	85
<i>FIGURE 8 GLOBAL SALES AND FORECASTS FOR NONBIOLOGIC ORPHAN DRUGS, 2008-2014 (\$ MILLIONS)</i>	86
<i>FIGURE 9 ORPHAN DRUGS MARKET BY TECHNOLOGY TYPE, 2009 AND 2014 (%)</i>	86
<i>FIGURE 9 (CONTINUED)</i>	87
CHAPTER SIX: APPLICATIONS.....	88
CANCER.....	88
LEUKEMIAS.....	88
Acute Lymphocytic/Lymphoblastic Leukemia	89
Acute Myelogenous/Myelocytic Leukemia.....	89
Chronic Lymphocytic Leukemia	89
Chronic Myelocytic/Myelogenous Leukemia	90
LYMPHOMAS	90
Hodgkin's Lymphoma.....	90
Non-Hodgkin's Lymphoma.....	91
MULTIPLE MYELOMA	91
SOLID TUMORS.....	91
ACROMEGALY	92

CANCER-RELATED CONDITIONS	92
<i>TABLE 45 ORPHAN DRUGS APPROVED BY U.S. FDA TO TREAT</i>	
<i>CANCER AND CANCER-RELATED CONDITIONS</i>	93
<i>TABLE 45 (CONTINUED)</i>	94
<i>TABLE 45 (CONTINUED)</i>	95
<i>TABLE 45 (CONTINUED)</i>	96
<i>TABLE 45 (CONTINUED)</i>	97
<i>TABLE 45 (CONTINUED)</i>	98
<i>TABLE 45 (CONTINUED)</i>	99
SALES OF LEADING ORPHAN PRODUCTS TO TREAT	
CANCER AND CANCER-RELATED CONDITIONS	99
<i>TABLE 46 GLOBAL MARKET FOR LEADING ORPHAN DRUGS TO</i>	
<i>TREAT CANCER, THROUGH 2014 (\$ MILLIONS)</i>	100
<i>FIGURE 10 GLOBAL MARKET FOR LEADING ORPHAN DRUGS TO</i>	
<i>TREAT CANCER AND CANCER RELATED CONDITIONS, 2008-2014</i>	
<i>(\$ MILLIONS)</i>	101
CARDIOVASCULAR DISEASES AND BLOOD DISORDERS	101
ANEMIA	101
HYPERCALCEMIA.....	102
HYPERTENSION	102
HYPOTENSION.....	102
NEUTROPENIA.....	102
TACHYARRHYTHMIAS/TACHYCARDIA.....	103
THROMBOCYTHEMIA.....	103
THROMBOCYTOPENIA	103
ORPHAN DRUGS APPROVED TO TREAT	
CARDIOVASCULAR DISEASES AND BLOOD DISORDERS....	103
<i>TABLE 47 APPROVED ORPHAN DRUGS TO TREAT</i>	
<i>CARDIOVASCULAR DISEASES AND BLOOD DISORDERS</i>	104
<i>TABLE 47 (CONTINUED)</i>	105
SALES OF LEADING ORPHAN PRODUCTS TO TREAT	
CARDIOVASCULAR DISEASES AND BLOOD	
DISORDERS: WORLDWIDE, THROUGH 2014.....	106
<i>TABLE 48 GLOBAL MARKET FOR LEADING ORPHAN DRUGS TO</i>	
<i>TREAT CARDIOVASCULAR DISEASES AND BLOOD DISORDERS,</i>	
<i>THROUGH 2014 (\$ MILLIONS)</i>	106
<i>FIGURE 11 GLOBAL MARKET FOR LEADING ORPHAN DRUGS TO</i>	
<i>TREAT CARDIOVASCULAR DISEASES AND BLOOD DISORDERS,</i>	
<i>2008-2014 (\$ MILLIONS)</i>	106
GASTROINTESTINAL DISEASES	107
CHOLELITHIASIS	107
ESOPHAGEAL VARICES	107
ORPHAN PRODUCTS APPROVED TO TREAT	
GASTROINTESTINAL DISEASES	107

<i>TABLE 49 APPROVED ORPHAN DRUGS TO TREAT</i>	
<i>GASTROINTESTINAL DISEASES</i>	108
SALES OF LEADING ORPHAN PRODUCTS TO TREAT	
GASTROINTESTINAL DISEASES	108
GENETIC DISEASES AND DISORDERS	108
ALPHA-1 PROTEINASE DEFICIENCY	109
FABRY DISEASE.....	109
GAUCHER'S DISEASE	110
HEMOPHILIA.....	110
MUCOPOLYSACCHARIDOSIS	111
TYROSINEMIA.....	111
ORPHAN PRODUCTS APPROVED TO TREAT GENETIC	
DISEASES AND DISORDERS	112
<i>TABLE 50 APPROVED ORPHAN DRUGS TO TREAT GENETIC</i>	
<i>DISEASES AND DISORDERS</i>	112
<i>TABLE 50 (CONTINUED)</i>	113
<i>TABLE 50 (CONTINUED)</i>	114
<i>TABLE 50 (CONTINUED)</i>	115
SALES OF LEADING ORPHAN PRODUCTS TO TREAT	
GENETIC DISEASES AND DISORDERS	115
<i>TABLE 51 GLOBAL MARKET FOR LEADING ORPHAN DRUGS TO</i>	
<i>TREAT GENETIC DISEASES AND DISORDERS, THROUGH 2014 (\$</i>	
<i>MILLIONS)</i>	115
<i>FIGURE 12 GLOBAL MARKET FOR LEADING ORPHAN DRUGS TO</i>	
<i>TREAT GENETIC DISEASES AND DISORDERS, 2008-2014 (\$</i>	
<i>MILLIONS)</i>	116
IMMUNE DISEASES	116
COMMON VARIABLE IMMUNODEFICIENCY	116
INTERSTITIAL CYSTITIS.....	117
JUVENILE RHEUMATOID ARTHRITIS	117
ORGAN TRANSPLANT REJECTION	118
ORPHAN PRODUCTS APPROVED TO TREAT IMMUNE AND	
AUTOIMMUNE DISEASES AND TRANSPLANT	
REJECTION	118
<i>TABLE 52 APPROVED ORPHAN DRUGS TO TREAT IMMUNE AND</i>	
<i>AUTOIMMUNE DISEASES/TRANSPLANT REJECTION</i>	118
<i>TABLE 52 (CONTINUED)</i>	119
SALES OF LEADING ORPHAN PRODUCTS TO TREAT	
IMMUNE AND AUTOIMMUNE DISEASES AND	
TRANSPLANT REJECTION	119
<i>TABLE 53 GLOBAL MARKET FOR LEADING ORPHAN DRUGS IN</i>	
<i>THE IMMUNE DISEASES SECTOR, THROUGH 2014 (\$ MILLIONS)</i>	119
<i>FIGURE 13 GLOBAL MARKET FOR LEADING ORPHAN DRUGS IN</i>	
<i>THE IMMUNE DISEASES SECTOR, 2008-2014 (\$ MILLIONS)</i>	120

INFECTIOUS DISEASES.....	120
ACQUIRED IMMUNE DEFICIENCY SYNDROME RELATED HEALTH CONDITIONS	120
CRYPTOCOCCAL MENINGITIS	121
CRYPTOSPORIDIOSIS	121
CYTOMEGALOVIRUS RETINITIS.....	121
GIARDIASIS.....	122
HYDATID DISEASE.....	122
KERATOCONJUNCTIVITIS	122
LEISHMANIASIS	122
LEPROSY	123
MALARIA	123
NEUROCYSTICERCOSIS.....	124
PNEUMOCYSTIC CARINII PNEUMONIA	124
RESPIRATORY SYNCYTIAL VIRUS.....	124
TUBERCULOSIS.....	124
ORPHAN PRODUCTS APPROVED TO TREAT INFECTIOUS DISEASES.....	125
<i>TABLE 54 APPROVED ORPHAN DRUGS TO TREAT INFECTIOUS DISEASES</i>	<i>125</i>
<i>TABLE 54 (CONTINUED).....</i>	<i>126</i>
<i>TABLE 54 (CONTINUED).....</i>	<i>127</i>
SALES OF LEADING ORPHAN PRODUCTS TO TREAT INFECTIOUS DISEASES.....	128
<i>TABLE 55 GLOBAL MARKET FOR LEADING ORPHAN DRUGS TO TREAT INFECTIOUS DISEASES, THROUGH 2014 (\$ MILLIONS).....</i>	<i>128</i>
<i>FIGURE 14 GLOBAL MARKET FOR LEADING ORPHAN DRUGS TO TREAT INFECTIOUS DISEASES, 2008-2014 (\$ MILLIONS)</i>	<i>128</i>
INFLAMMATORY DISEASES	129
ANKYLOSING SPONDYLITIS.....	129
CROHN'S DISEASE	129
ORPHAN PRODUCTS APPROVED TO TREAT INFLAMMATORY DISEASES	129
<i>TABLE 56 APPROVED ORPHAN DRUGS TO TREAT INFLAMMATORY DISEASES</i>	<i>130</i>
SALES OF LEADING ORPHAN PRODUCTS TO TREAT INFLAMMATORY DISEASES	130
<i>TABLE 57 GLOBAL MARKET FOR LEADING ORPHAN DRUGS TO TREAT INFLAMMATORY DISEASES, THROUGH 2014 (\$ MILLIONS).....</i>	<i>131</i>
<i>FIGURE 15 GLOBAL MARKET FOR LEADING ORPHAN DRUGS TO TREAT INFLAMMATORY DISEASES, 2008-2014 (\$ MILLIONS).....</i>	<i>131</i>
NEUROLOGICAL DISEASES AND DISORDERS.....	131
BLEPHAROSPASM.....	132

DYSTONIA.....	132
LENNOX-GASTAUT SYNDROME.....	132
MULTIPLE SCLEROSIS.....	133
NARCOLEPSY/CATAPLEXY.....	133
STRABISMUS.....	133
ORPHAN PRODUCTS APPROVED TO TREAT NEUROLOGICAL DISEASES AND DISORDERS.....	134
<i>TABLE 58 APPROVED ORPHAN DRUGS FOR NEUROLOGICAL DISEASES AND DISORDERS.....</i>	<i>134</i>
<i>TABLE 58 (CONTINUED).....</i>	<i>135</i>
SALES OF LEADING ORPHAN PRODUCTS TO TREAT NEUROLOGICAL DISEASES AND DISORDERS.....	135
<i>TABLE 59 GLOBAL MARKET FOR LEADING ORPHAN DRUGS TO TREAT NEUROLOGICAL DISEASES AND DISORDERS, THROUGH 2014 (\$ MILLIONS).....</i>	<i>136</i>
<i>FIGURE 16 GLOBAL MARKET FOR LEADING ORPHAN DRUGS TO TREAT NEUROLOGICAL DISEASES AND DISORDERS, 2008-2014 (\$ MILLIONS).....</i>	<i>136</i>
REPRODUCTIVE DISEASES AND DISORDERS	137
AMENORRHEA	137
PRECOCIOUS PUBERTY.....	137
IMPAIRED SPERMATOGENESIS.....	138
ORPHAN PRODUCTS APPROVED TO TREAT REPRODUCTIVE DISEASES	138
<i>TABLE 60 APPROVED ORPHAN DRUGS TO TREAT REPRODUCTIVE DISEASES AND DISORDERS.....</i>	<i>138</i>
<i>TABLE 60 (CONTINUED).....</i>	<i>139</i>
SALES OF LEADING ORPHAN PRODUCTS TO TREAT REPRODUCTIVE DISEASES AND DISORDERS	139
<i>TABLE 61 GLOBAL MARKET FOR LEADING ORPHAN DRUGS TO TREAT: REPRODUCTIVE DISEASES AND DISORDERS, THROUGH 2014 (\$ MILLIONS).....</i>	<i>139</i>
<i>FIGURE 17 GLOBAL MARKET FOR LEADING ORPHAN DRUGS TO TREAT REPRODUCTIVE DISEASES AND DISORDERS, 2008-2014 (\$ MILLIONS).....</i>	<i>140</i>
RESPIRATORY DISEASES	140
HYALINE MEMBRANE.....	140
MALIGNANT PLEURAL EFFUSION.....	141
PULMONARY HYPERTENSION.....	141
ORPHAN PRODUCTS APPROVED TO TREAT RESPIRATORY DISEASES.....	141
<i>TABLE 62 APPROVED ORPHAN DRUGS FOR RESPIRATORY DISEASES</i>	<i>142</i>

SALES OF LEADING ORPHAN PRODUCTS TO TREAT RESPIRATORY DISEASES	143
TABLE 63 GLOBAL MARKET FOR LEADING ORPHAN DRUGS TO TREAT: RESPIRATORY DISEASES, THROUGH 2014 (\$ MILLIONS).....	143
FIGURE 18 GLOBAL MARKET FOR LEADING ORPHAN DRUGS TO TREAT RESPIRATORY DISEASES, 2008-2014 (\$ MILLIONS)	143
OTHER SELECTED RARE DISEASES AND DISORDERS FOR WHICH ORPHAN PRODUCTS ARE AVAILABLE	144
CHRONIC GRANULOMATOUS DISEASE	144
CYSTINOSIS	144
HOMOCYSTINURIA	144
MASTOCYTOSIS	145
PAGET'S DISEASE.....	145
ORPHAN PRODUCTS APPROVED TO TREAT MISCELLANEOUS DISEASES AND DISORDERS	145
TABLE 64 APPROVED ORPHAN DRUGS FOR MISCELLANEOUS INDICATIONS.....	146
TABLE 64 (CONTINUED).....	147
TABLE 64 (CONTINUED).....	148
TABLE 64 (CONTINUED).....	149
SALES OF LEADING ORPHAN PRODUCTS TO TREAT MISCELLANEOUS DISEASES AND DISORDERS	149
TABLE 65 GLOBAL MARKET FOR LEADING ORPHAN DRUGS TO TREAT: MISCELLANEOUS DISEASES AND DISORDERS, THROUGH 2014 (\$ MILLIONS).....	150
FIGURE 19 GLOBAL MARKET FOR LEADING ORPHAN DRUGS TO TREAT MISCELLANEOUS DISEASES AND DISORDERS, 2008-2014 (\$ MILLIONS).....	150
THERAPEUTIC AREAS WITH THE HIGHEST REVENUES FROM ORPHAN DRUGS IN 2009 AND THEIR FUTURE GROWTH PROSPECTS.....	150
TABLE 66 GLOBAL MARKET FOR LEADING ORPHAN DRUGS IN KEY THERAPEUTIC AREAS, THROUGH 2014 (\$ MILLIONS).....	151
FIGURE 20 GLOBAL MARKET FOR LEADING ORPHAN DRUGS IN KEY THERAPEUTIC AREAS, 2009 AND 2014 (%)	152
FIGURE 20 (CONTINUED)	153
CHAPTER SEVEN: LEGISLATION AND REGULATORY ENVIRONMENT	154
LEGISLATION IN THE U.S.	154
RARE DISEASES ACT AND RARE DISEASES ORPHAN PRODUCT DEVELOPMENT ACT OF 2002	155
INCENTIVES FOR ORPHAN DRUG DEVELOPMENT IN THE U.S.	155
Market Exclusivity for 7 Years Following Market Approval.....	155

Tax Credits — 50% of the Cost of Clinical Trials	
Undertaken in the U.S.....	155
FDA Grants for Clinical Trials	156
Technical and Administrative Assistance with the	
Identification and Development of Orphan Products	156
Exemption from Prescription Drug User Fee Act (PDUFA)	
— Waiver of Application Fee	156
Fast-track Approvals	156
IMPACT OF THE ORPHAN DRUG ACT IN THE PHARMA	
AND BIOTECH INDUSTRIES	156
FIGURE 21 NUMBER OF ORPHAN DRUG DESIGNATIONS IN THE	
U.S., 1983-2009	157
FIGURE 21 (CONTINUED)	158
FIGURE 22 ORPHAN DRUG APPROVALS IN THE U.S. (1983-2009)	158
WAYS TO CIRCUMVENT MARKET EXCLUSIVITY	159
SOME IMPORTANT PUBLIC AGENCIES INVOLVED IN	
ORPHAN DRUG REGULATION AND PROMOTION IN	
THE U.S.	159
TABLE 67 PUBLIC/NONPROFIT AGENCIES INVOLVED IN ORPHAN	
DRUG REGULATION AND PROMOTION IN THE U.S.....	159
TABLE 67 (CONTINUED).....	160
IMPROVING ACCESS TO CLINICAL TRIALS ACT OF 2009	160
LEGISLATION — EUROPEAN UNION.....	160
TABLE 68 LIST OF ORPHAN DRUGS APPROVED BY EU, 2000-2009.....	161
TABLE 68 (CONTINUED).....	162
TABLE 68 (CONTINUED).....	163
INCENTIVES FOR ORPHAN DRUG DEVELOPMENT IN THE	
EU	164
10 Years of Post-approval Market Exclusivity	164
Protocol Assistance	164
Access to a Centralized Community Procedure for	
Marketing Authorization with a 50% Reduction in the	
Fee.....	164
Other Fee Reductions	165
Development Grants.....	165
ORPHAN DESIGNATION PROCESS IN EU	165
MAIN PUBLIC AGENCIES INVOLVED IN ORPHAN DRUG	
REGULATION AND PROMOTION IN THE EU.....	165
TABLE 69 MAIN PUBLIC/NONPROFIT AGENCIES INVOLVED IN	
ORPHAN DRUG REGULATION AND PROMOTION IN THE EU	166
AVAILABILITY OF ORPHAN DRUGS IN THE MEMBER	
STATES OF THE EU	167
TABLE 70 COUNTRY-WISE SUMMARY OF NATIONAL MEASURES	
RELATED TO ORPHAN DRUG LEGISLATION IN EU	167

<i>TABLE 70 (CONTINUED)</i>	168
<i>TABLE 70 (CONTINUED)</i>	169
<i>TABLE 70 (CONTINUED)</i>	170
INITIATIVES BY EMEA TO SPEED UP APPROVAL PROCESS.....	170
CONVERGENCE OF REGULATORY PRACTICES OF EMEA AND FDA FOR ORPHAN DRUG APPROVALS – AN EMERGING TREND.....	170
LEGISLATION — JAPAN	171
LEGISLATION — AUSTRALIA	172
LEGISLATION — SINGAPORE.....	173
LEGISLATION STATUS — OTHER COUNTRIES/REGIONS	174
TAIWAN	174
KOREA	174
HONG KONG	175
CANADA.....	175
SWITZERLAND	175
ISRAEL.....	176
BRAZIL.....	176
LEGISLATION COMPARISON — SUMMARY.....	176
<i>TABLE 71 COMPARISON OF ORPHAN DRUG LEGISLATION IN THE U.S., EU, AUSTRALIA, AND JAPAN</i>	<i>177</i>
<i>TABLE 71 (CONTINUED)</i>	<i>178</i>
CALL FOR MODIFICATIONS OF ORPHAN DRUG LEGISLATION	178
CORRELATION BETWEEN MARKET EXCLUSIVITY AND THE HIGH PRICE OF ORPHAN DRUGS.....	179
<i>TABLE 72 ORPHAN DRUGS APPROVED FOR PULMONARY ARTERIAL HYPERTENSION (PAH) IN THE U.S. AND EU</i>	<i>180</i>
IMPACT OF BIOSIMILARS ON THE ORPHAN DRUGS SECTOR	181
FACTORS LEADING TO THE DELAY IN IMPLEMENTING REGULATIONS ON BIOGENERICS IN THE U.S.	182
CHAPTER EIGHT: TECHNOLOGY TRENDS ANALYSIS.....	183
PATENT ANALYSIS	183
LEADING ORPHAN DRUGS AND RELATED PATENTS.....	183
<i>TABLE 73 LEADING ORPHAN DRUGS AND THEIR RELEVANT U.S. PATENTS.....</i>	<i>184</i>
<i>TABLE 73 (CONTINUED)</i>	<i>185</i>
<i>TABLE 73 (CONTINUED)</i>	<i>186</i>
TECHNOLOGY TRENDS ANALYSIS BASED ON ORPHAN DRUG APPROVALS.....	186
GENERAL TRENDS.....	187
<i>TABLE 74 PERCENTAGE OF BIOLOGICS IN ORPHAN DRUG APPROVALS, 1983-2009.....</i>	<i>187</i>

<i>FIGURE 23 ORPHAN DRUG APPROVAL TRENDS: BIOLOGICS VERSUS NONBIOLOGICS</i>	188
TRENDS BY PRODUCT TYPES.....	188
<i>FIGURE 24 ORPHAN DRUG APPROVALS BY PRODUCT TYPES, 2009 (%)</i>	189
CONCLUSIONS OF TECHNICAL TRENDS ANALYSIS.....	190
CHAPTER NINE: COMPANY PROFILES	191
ABBOTT LABORATORIES.....	191
ACTELION PHARMACEUTICALS.....	192
AMGEN, INC.	192
BAYER AG	193
<i>TABLE 75 ORPHAN DRUG PORTFOLIO OF BAYER – MARKETED AND BEING DEVELOPED</i>	193
<i>TABLE 75 (CONTINUED)</i>	194
BIOGEN IDEC, INC.	194
CELGENE CORPORATION	195
ELI LILLY AND COMPANY	195
<i>TABLE 76 ORPHAN DRUGS MARKETED AND BEING DEVELOPED BY ELI LILLY</i>	196
GENZYME CORPORATION.....	196
F. HOFFMANN-LA ROCHE, LTD.....	197
<i>TABLE 77 ORPHAN DRUG DEVELOPMENT PROGRAMS BY ROCHE</i>	198
JOHNSON & JOHNSON	198
<i>TABLE 78 ORPHAN DRUG DEVELOPMENT PROGRAMS OF J&J</i>	199
NOVARTIS INTERNATIONAL AG.....	199
MERCK & CO, INC.	200
<i>TABLE 79 ORPHAN DRUG DEVELOPMENT PROGRAMS BY MERCK</i>	201
PFIZER, INC.....	201
<i>TABLE 80 ORPHAN DRUG DEVELOPMENT PROGRAMS BY PFIZER</i>	202
GLOSSARY	203
<i>TABLE 81 GLOSSARY</i>	203
<i>TABLE 81 (CONTINUED)</i>	204
<i>TABLE 81 (CONTINUED)</i>	205